Fibrates in Pediatric Cholestasis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-01

Study Completion Date

2018-06-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study conducted to assess the effect of fibrates on pruritus and biochemical picture in pediatric patients with cholestatic liver diseases.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in Neonates

NCT00846963

Cholestasis

COMPLETED PHASE2/PHASE3

Steroids in Fulminant Hepatitis A in the Pediatric Age Group

NCT02375867

Fulminant Hepatic Failure

COMPLETED PHASE4

Evaluation of the Use of Granulocyte Colony Stimulating Factor (GCSF) in Post Kasai Type 3 Biliary Atresia

NCT06708572

Granulocyte Colony-stimulating Factor Biliary Atresia

RECRUITING NA

Role of Fenofibrate in Indirect Neonatal Hyperbilirubinemia: a Randomized Control Trial

NCT04868019

Hyperbilirubinemia, Neonatal

UNKNOWN NA

Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis

NCT01088607

Primary Sclerosing Cholangitis

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cholestatic liver disorders include a spectrum of hepatobiliary diseases of diverse etiologies that are characterized by impaired hepatocellular secretion of bile, resulting in accumulation of bile acids, bilirubin and cholesterol.This could result in different clinical features including pruritus, malabsorption and vitamin deficiencies with subsequent coagulation disorders and bone disease. Persistence of cholestasis leads to biliary fibrosis which can progress to liver cirrhosis and end-stage liver disease.

Nuclear receptors (NRs) regulate ligand-activated transcription factor networks of genes for the elimination and detoxification of potentially toxic biliary constituents accumulating in cholestasis. Activation of several NRs also modulates fibrogenesis, inflammation, and carcinogenesis as sequelae of cholestasis. Hence, It represent attractive targets for pharmacotherapy of cholestatic disorders.

Several already available drugs may exert their beneficial effects in cholestasis via NR activation eg, ursodeoxycholic acid via glucocorticoid receptor and pregnane X receptor, and rifampicin via pregnane X receptor. Unfortunately, Some patients may not respond to these medications.

Fibrates, serum Lipid lowering medication, has a stimulation action on proliferator activated receptor alpha. It is a nuclear receptor with an integral role in bile homeostasis. Several case reports and pilot studies have demonstrated the efficacy of fibrates in reducing serum biomarkers of cholestasis and liver function abnormalities in patients with incomplete response to ursodeoxycholic acid monotherapy. These results are of interest, because fibrates are attracting increased attention as adjunct therapy for chronic cholestatic liver diseases.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Cholestasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ursogal

Control group : Ursogal 10-20 mg/kg/d on 2 divided dose for four months with regular follow up.

Group Type ACTIVE_COMPARATOR

Ursogal

Intervention Type DRUG

suspension

Lipanthyl + Ursogal

Therapy group: Ursogal 10-20 mg/kg/d by mouth, on 2 divided dose, and lipanthyl 10-20 mg/kg/d by mouth,once per day, for four months with regular follow up.

Group Type EXPERIMENTAL

Lipanthyl

Intervention Type DRUG

Tablet

Ursogal

Intervention Type DRUG

suspension

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lipanthyl

Tablet

Intervention Type DRUG

Ursogal

suspension

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ursogal non

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with chronic cholestatic liver disease defined as any condition in which substances normally excreted into bile are retained for more than 6 months.

Exclusion Criteria

* Patients with anatomical or mechanical obstructive causes for cholestasis.
* Cholestatic patients who were suffering from another liver disease.
* Cholestatic patients who were receiving drugs affecting lipid profile.
* Patients receiving drugs that interact with Fenofibrate (FF) e.g statins and warfarin
* Patients with non obstructive gall bladder stones were excluded from T gp.

Minimum Eligible Age

6 Months

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No